A Video View
Visit our YouTube channel to view Project A.L.I.V.E. videos here and take a "behind the scenes" look at our partnership with Dr. Sharon Dudley-Brown of Johns Hopkins Medicine.
We are conducting a study with the Meyerhoff Inflammatory Bowel Disease Center of the Johns Hopkins University School of Medicine to “implement and evaluate the effectiveness of an Inflammatory Bowel Disease (IBD) Medication Therapy Management (MTM) patient fulfillment model compared to standard care in a large university hospital setting.”
Announced in 2014, Project “A.L.I.V.E” (Adherence and Long-term IBD Value-added Effectiveness), sought to focus on the chronic, debilitating conditions of crohn’s disease (CD) and ulcerative colitis (UC). Curant Health Director of Clinical Services, Vickie Andros; MTM Pharmacist, Krystin Tran and Principal Investigator and Assistant Professor of Medicine at Johns Hopkins University, Dr. Sharon Dudley-Brown led the study.
Revisiting the Project A.L.I.V.E. abstract
According to the study abstract, the absence of an integrated MTM platform in IBD care limits the ability to track and fully understand patient outcomes including Adverse Drug Events (ADE’s), hospital readmissions and long-term adherence rates. Systematic review of the literature validates there is no reported long term adherence data for CD or UC. Likewise, no data has been published evaluating the impact of MTM on IBD outcomes.
During each MTM session with the patient, pharmacists will complete medication reconciliation, identify any medication related issues, monitor therapy and provide patient education on the importance of adherence with treatment and provider follow-up, instructions on how to take/administer medications and side effects of medications.
Results will be evaluated at 30 days, 60 days, six months, nine months and 12 months from the initiation of the IBD MTM patient fulfillment model. Vickie Andros, PharmD, Director of Clinical Services at Curant Health, presented interim study results at the 2016 Annual ACG Scientific Meeting.
Reviewing the Results to Date
At the time of the poster presentation, 110 subjects had been randomized and 24 had been excluded from the study, primarily due to insurance restrictions to specialty pharmacy. Out of the 86 enrolled patients:
- 55% of patients in the intervention arm were considered to have improved adherence
- Among those who had at least three prescription fills, 100% in the intervention arm and 90% in the control 1 arm were considered adherent to treatment
- Significantly more subjects receiving MTM and fulfillment of medications showed improved adherence per MMAS-8 over time.
View full interim study results, here.
To learn more about Curant Health, contact Kristin Lindsey, Senior Marketing Director, at email@example.com.